accepting new patients

My main academic and clinical objective is to, if not cure, at least contribute to significantly better outcomes for patients with Myelodysplastic Syndromes (MDS). I am the Chief of the Section of MDS in the Department of Leukemia at MD Anderson Cancer Center. I have built this into the largest clinical program of its class. One hundred percent of my research and clinical effort is devoted to patients with MDS.

Dr. Cogle is an associate professor of medicine at the University of Florida, Gainesville. He has clinical and research expertise in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and allogeneic hematopoietic cell transplant. Dr. Cogle leads a research laboratory that studies the biology of MDS and AML, and his group has successfully translated his discoveries into new treatments for patients. Dr. Cogle’s goal is to fi nd cures for MDS and leukemia, educate patients and providers about the distinct heterogeneity of these diseases, educate policy makers that blood cancers are a

Dr. Odenike is Professor of Medicine and Director of the Leukemia Program at the University of Chicago. Her clinical interests are in acute and chronic leukemias, myeloproliferative neoplasms, myelodysplastic syndromes, and stem cell transplantation. Her research is focused on the development of novel therapeutic agents for the treatment of acute and chronic leukemias, and chronic myeloproliferative diseases, with the ultimate goal of improving treatment options for patients with these diseases. She is the principal investigator on a number of clinical trials investigating molecularly targeted

Gail J. Roboz, M.D. is a professor of medicine and Director of the Clinical and Translational Leukemia Programs at the Weill Medical College of Cornell University and the NewYork Presbyterian Hospital in New York City. Dr. Roboz graduated summa cum laude from Yale University and received her medical degree from The Mount Sinai School of Medicine in New York, where she was elected to the Alpha Omega Alpha Honor Medical Society and achieved the highest academic standing in the graduating class. She completed her internship in internal medicine at The Beth Israel Hospital in Boston and a

Steven Gore, MD, is an internationally recognized hematologist specializing in the treatment of leukemia and myelodysplastic syndrome. When treating patients with these complicated conditions, he believes in providing as much information as possible so they can make their own decisions about treatment. Because he believes this is so important, Dr. Gore will often ask patients to explain what they know back to him. “I'm the advice-giver, but the patient is always in the driver's seat in terms of choosing strategies for their care,” he says. In addition, Dr. Gore discusses expectations and

Aristoteles Giagounidis is Head of the Department of Oncology, Haematology, and Palliative Care at Marien Hospital in Düsseldorf, Germany. After earning his medical degree in 1992 from Eberhard-Karls-University in Tübingen, Germany, Dr Giagounidis was house officer at the Withybush General Hospital in Haverfordwest, Wales, and at the William Harvey Hospital in Ashford, Kent, UK. He then served as resident physician at the Haematology/Oncology Department of Heinrich-Heine- University in Düsseldorf, where he became board certified in 1999. Due to his special expertise in haematological cytology

Amer Zeidan’s primary research interest is in myelodysplastic syndromes (MDS) and was mentored in this research area by Dr. Steven Gore and Dr. B Douglas Smith at Johns Hopkins University where he has completed a clinical hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes. He also earned a Master of Health Science (MHS) degree in Clinical Investigation at Johns Hopkins before recently moving to Yale University as an Assistant Professor of Medicine to reunite with Dr. Steven Gore and continue his MDS research. Dr. Zeidan has two major areas of

In 2008 Dr. Risitano received a grant for the research project, "Genetic Fingerprint of Complement and Complement-related Genes in PNH: Relationship with Pathophysiology, Clinical Manifestations (including Thrombosis) and Response to Eculizamab PNH Foundation." We recently caught up with Dr. Risitano and asked how the grant helped him add to the understanding of bone marrow failure disease and where his current research is. The grant contributed to allowing Dr. Risitano to perform research that has unraveled novel mechanisms of disease in PNH. Risitano and his team were first able to

Dr. Eric Padron is a junior investigator, having completed his fellowship in hematology/oncology at the Moffitt Cancer Center in Florida. He describes his area of interest in bone marrow failure disease as focused on Chronic Myelomonocytic Leukemia (CMML), which is related to Myelodysplastic Syndromes (MDS). Although he looks forward to his weekly clinic day when he is able to see patients with MDS, he also notes that the two year fellowship he received through the Edward P. Evans Foundation was invaluable in allowing him to protect some of his time from other clinical duties, and focus on his

Dr. Hetty Caraway received her medical degree from the University of Massachusetts Medical School in Worcester, Massachusetts. She completed her internship and residency in internal medicine, and her fellowship in medical oncology at Johns Hopkins University in Baltimore. In addition to her medical training, Dr. Carraway earned an MBA from the Carey Business School at Johns Hopkins University in the Business of Health. She is currently a Staff Physician at the Taussig Cancer Institute in the Division of Hematologic Oncology and Blood Disorders at the Cleveland Clinic. Dr. Carraway is American